Richard Buller Sells 9,000 Shares of Celcuity (NASDAQ:CELC) Stock

Celcuity, Inc. (NASDAQ:CELC) Director Richard Buller sold 9,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. This trade represents a 57.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Celcuity Trading Down 1.6%

Celcuity stock traded down $2.25 during trading on Wednesday, hitting $139.44. The company had a trading volume of 801,530 shares, compared to its average volume of 798,960. Celcuity, Inc. has a 1-year low of $9.51 and a 1-year high of $151.02. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20. The company’s 50 day simple moving average is $115.27 and its 200-day simple moving average is $103.28. The stock has a market cap of $6.74 billion, a price-to-earnings ratio of -36.79 and a beta of 0.09.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.09. As a group, analysts expect that Celcuity, Inc. will post -3.97 EPS for the current fiscal year.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Phase‑III headline: gedatolisib outperformed Novartis’ Piqray and showed a survival benefit in PIK3CA+ metastatic breast cancer — the clinical win is the primary fundamental catalyst that drove recent buying and acquisition speculation. Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3
• Positive Sentiment: Analyst support: Guggenheim reiterated a Buy and other firms (Needham) issued positive forecasts and price‑target increases, reinforcing investor confidence and fueling takeover chatter. Guggenheim Keeps Their Buy Rating on Celcuity (CELC) Needham & Company LLC Issues Positive Forecast for Celcuity
• Neutral Sentiment: Valuation debate: commentary asks whether a ~13x one‑year surge leaves meaningful upside from here — this frames mixed investor sentiment despite the clinical win. Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?
• Negative Sentiment: Near‑term estimate trims: HC Wainwright slightly lowered Q1–Q3/Q2 2026 EPS forecasts (small downgrades) — a signal that near‑term cash burn, timing of revenues or costs could be risk factors even as they lift long‑term projections. (Research note released 5/4/2026)
• Negative Sentiment: Technical/profit‑taking pressure: stock is trading near its 1‑year high after a rapid rally; modestly elevated volume and the high headline valuation increase the odds of short‑term pullbacks as some investors lock in gains.

Analysts Set New Price Targets

CELC has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Monday, April 20th. Craig Hallum reissued a “buy” rating and issued a $189.00 price target on shares of Celcuity in a research report on Monday. Guggenheim raised their price target on shares of Celcuity from $135.00 to $165.00 and gave the company a “buy” rating in a research report on Monday. Citizens Jmp raised their price target on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research report on Monday. Finally, Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $134.50.

Hedge Funds Weigh In On Celcuity

Institutional investors and hedge funds have recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its stake in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Celcuity during the fourth quarter worth $42,000. Ogorek Anthony Joseph NY ADV acquired a new position in shares of Celcuity during the third quarter worth $27,000. US Bancorp DE grew its stake in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares in the last quarter. Finally, NBC Securities Inc. acquired a new position in shares of Celcuity during the fourth quarter worth $99,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.